{
    "clinical_study": {
        "@rank": "78798", 
        "arm_group": [
            {
                "arm_group_label": "Implanted subject", 
                "description": "Subjects with Interstim implanted"
            }, 
            {
                "arm_group_label": "Controls", 
                "description": "Subjects without Interstim implanted"
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this study is to compare protein markers in the urine of patients with and\n      without overactive bladder (OAB) and InterStim\u00ae. Specifically, we will look for changes in\n      protein markers that might reflect bladder symptoms before and after InterStim\u00ae implant."
        }, 
        "brief_title": "Urinary Biomarkers For Objective Measurement Of InterStim\u00ae Response In Over Active Bladder (OAB) Patients.", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Overactive Bladder", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "OAB subjects (n=10 Phase I and n=10 Phase II)\n\n        Inclusion Criteria:\n\n          -  Female\n\n          -  Age 18-75 years\n\n          -  Clinical symptoms of OAB (urgency and frequency with or without urge incontinence)\n             for at least 3 or the 6 months immediately before the first visit.\n\n          -  At least 8 voids/day and an average of 1 nocturnal void over 3 consecutive days on\n             baseline bladder diary.\n\n          -  InterStim\u00ae treatment na\u00efve or being revised with a new lead\n\n        Exclusion Criteria:\n\n          -  Pelvic mass, pelvic prolapse, urinary retention, and pelvic malignancies as revealed\n             by physical examination/medical record review\n\n          -  Implanted Programmable Generator (IPG) is not implanted/connected to the tined lead\n             (failed Stage I)\n\n          -  Revision of only the IPG (without replacement of the tined lead)\n\n          -  More than one InterStim\u00ae device being placed (undergoing bilateral stimulation)\n\n        Controls (n=10)\n\n        Inclusion:\n\n          -  Female\n\n          -  Age 18-75 years\n\n          -  Deny history of OAB diagnosis or symptoms (urgency and frequency with or without urge\n             incontinence)\n\n          -  American Urological Association (AUA) symptom score of \u22644\n\n        Exclusion:\n\n        -History of pelvic mass, prolapse, urinary retention, or pelvic malignancy within the last\n        year"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects with either have OAB and will be undergoing an InterStim\u00ae implant (InterStim\u00ae\n        group) or do not have bladder symptoms or an InterStim\u00ae device (Control group)"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739946", 
            "org_study_id": "2012-143"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Royal Oak", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48073"
                }, 
                "name": "William Beaumont Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Urinary Biomarkers For Objective Measurement Of InterStim\u00ae Response In Over Active Bladder (OAB) Patients.", 
        "overall_official": {
            "affiliation": "William Beaumont Hospitals", 
            "last_name": "Michael Chancellor, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The proposed work will determine the variability of NGF and chemokine/cytokine levels in OAB patients and controls and the modulation of these levels by InterStim\u00ae.", 
            "measure": "Variability of Nerve Growth Factor (NGF) and Chemokine/cytokine levels", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739946"
        }, 
        "responsible_party": {
            "investigator_affiliation": "William Beaumont Hospitals", 
            "investigator_full_name": "Michael Chancellor, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "William Beaumont Hospitals", 
        "sponsors": {
            "collaborator": {
                "agency": "William Beaumont Hospitals", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Michael Chancellor, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}